Cystic Fibrosis - Institute for Respiratory Health

Cystic Fibrosis

Study Outline

The study aims to evaluate the effects of elexacaftor/tezacaftor/ivacaftor on cough and physical activity using wearable technology.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at or phone 6151 0888.

Eligibility & Requirements

  • Aged 18 or over with a diagnosis of cystic fibrosis and the F508del/MF mutation

What's Involved

  • Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted
  • Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes)
Principal Investigator
Dr Siobhain Mulrennan
This Clinical Trial is currently Closed

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Current Clinical Trials